Education
About Us
Working with TipRanks
Follow Us
Mannkind Corp. (MNKD)
NASDAQ:MNKD
MNKD Stock Chart & Stats
$5.63
-$0.05(-0.80%)
At close: 4:00 PM EST
$5.63
-$0.05(-0.80%)
Day’s Range― - ―
52-Week Range$3.38 - $7.48
Previous CloseN/A
Volume434.88K
Average Volume (3M)4.63M
Market Cap
$1.86B
Enterprise Value$1.64B
Total Cash (Recent Filing)$260.04M
Total Debt (Recent Filing)$46.48M
Price to Earnings (P/E)60.4
Beta0.82
Next Earnings
Mar 03, 2026EPS Estimate
<0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.03
Shares Outstanding306,828,340
10 Day Avg. Volume4,644,081
30 Day Avg. Volume4,626,298
Financial Highlights & Ratios
PEG Ratio-0.20
Price to Book (P/B)-22.39
Price to Sales (P/S)6.18
P/FCF Ratio53.77
Enterprise Value/Market Cap0.88
Enterprise Value/Revenue5.22
Enterprise Value/Gross Profit6.82
Enterprise Value/Ebitda22.11
Forecast
1Y Price Target
$10.67Price Target Upside89.52% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Market AdoptionStrong physician interest in screening IPF patients for pulmonary hypertension, due to positive study data, could boost Tyvaso uptake.
Product LaunchThe planned launch of new Tyvaso DPI cartridges aims to improve dosing convenience, potentially enhancing patient adherence and satisfaction.
Revenue GrowthTyvaso DPI net revenue exceeded expectations, which should result in higher royalty payments for MannKind Corporation.
Bears Say
Clinical Program ChallengesMost clinical programs for IPF have failed due to challenges including disease heterogeneity and variable disease course.
Competitive Pricing PressureThe announcement that Lasix ONYU will be priced at a wholesale acquisition cost of ~50% of that of Furoscix was the largest driver of MNKD weakness.
Product Efficacy ConcernsThe most frequently documented side effect from real world use of Afrezza is lack of efficacy, and data revealed that under-dosing was the reason.
MannKind News
MNKD FAQ
What was Mannkind Corp.’s price range in the past 12 months?
Mannkind Corp. lowest stock price was $3.38 and its highest was $7.48 in the past 12 months.
What is Mannkind Corp.’s market cap?
Mannkind Corp.’s market cap is $1.86B.
When is Mannkind Corp.’s upcoming earnings report date?
Mannkind Corp.’s upcoming earnings report date is Mar 03, 2026 which is in 115 days.
How were Mannkind Corp.’s earnings last quarter?
Mannkind Corp. released its earnings results on Nov 05, 2025. The company reported $0.03 earnings per share for the quarter, beating the consensus estimate of $0.019 by $0.011.
Is Mannkind Corp. overvalued?
According to Wall Street analysts Mannkind Corp.’s price is currently Undervalued.
Does Mannkind Corp. pay dividends?
Mannkind Corp. does not currently pay dividends.
What is Mannkind Corp.’s EPS estimate?
Mannkind Corp.’s EPS estimate is <0.01.
How many shares outstanding does Mannkind Corp. have?
Mannkind Corp. has 306,828,340 shares outstanding.
What happened to Mannkind Corp.’s price movement after its last earnings report?
Mannkind Corp. reported an EPS of $0.03 in its last earnings report, beating expectations of $0.019. Following the earnings report the stock price went up 10.584%.
Which hedge fund is a major shareholder of Mannkind Corp.?
Currently, no hedge funds are holding shares in MNKD
MannKind Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$10.67 (89.52% Upside)
$10.67 (89.52% Upside)
Blogger Sentiment
Bullish
MNKD Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 101.3K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▼ 0.2%
Last 30 Days ▲ 8.0%
Last 30 Days ▲ 8.0%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-23.81%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
6.56%
Trailing 12-Months
Company Description
Mannkind Corp.
MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes. It also promotes Thyquidity to adult and pediatric endocrinologists, and other healthcare providers for the treatment of hypothyroidism. The company has a license and collaboration agreement with United Therapeutics Corporation. It also has an agreement with NRx Pharmaceuticals to develop a dry powder formulation of ZYESAMI (aviptadil), a synthetic form of human vasoactive intestinal peptide to help protect cells against inflammatory conditions. MannKind Corporation was incorporated in 1991 and is headquartered in Westlake Village, California.
MNKD Company Deck
MNKD Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted strong revenue performance driven by Tyvaso DPI and Afrezza, alongside strategic growth initiatives such as the acquisition of scPharmaceuticals. However, challenges such as a decline in VGo revenue and increased SG&A expenses were noted. Overall, the positive aspects of revenue growth and strategic acquisitions outweighed the lowlights.View all MNKD earnings summariesMNKD Stock 12 Month Forecast
Average Price Target
$10.67
▲(89.52% Upside)
Technical Analysis
Ownership Overview
2.86% Insiders
11.10% Mutual Funds
0.07% Other Institutional Investors
72.75% Public Companies and Individual Investors